These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8893889)

  • 1. Economic value of gemcitabine in non-small cell lung cancer.
    Copley-Merriman C; Martin C; Johnson N; Sacristan JA; Drings PA; Bosanquet N
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):90-8. PubMed ID: 8893889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
    Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
    Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
    Koch P; Johnson N; van Schaik J; Andersen S; Blatter J; Bosanquet N; Copley-Merriman K; Drings P
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():49-54. PubMed ID: 8718425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
    Sacristán JA; Kennedy-Martin T; Rosell R; Cardenal F; Antón A; Lomas M; Alberola V; Massuti B; Carrato A; Minshall M
    Lung Cancer; 2000 May; 28(2):97-107. PubMed ID: 10717327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
    Noble S; Goa KL
    Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
    Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
    Tennvall GR; Fernberg JO
    Med Oncol; 1998 Jul; 15(2):129-36. PubMed ID: 9789222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
    Manegold C; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen P; Liippo K; Mattson K; van Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; van Walree N; ten Bokkel-Huinink W
    Ann Oncol; 1997 Jun; 8(6):525-9. PubMed ID: 9261520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.
    Manegold C
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):18-22. PubMed ID: 9728580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
    Lees M; Aristides M; Maniadakis N; McKendrick J; Botwood N; Stephenson D
    Pharmacoeconomics; 2002; 20(5):325-37. PubMed ID: 11994042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
    Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer].
    Yokoyama A
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1294-300. PubMed ID: 10945029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
    ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C
    Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer.
    Minshall ME; Liepa AM
    Am J Manag Care; 1998 Nov; 4(11):1591-602. PubMed ID: 10338905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy of stage IV non-small-cell lung cancer: contribution of gemcitabine].
    Souquet PJ; Gérinière L
    Rev Pneumol Clin; 2000 Nov; 56(5):315-9. PubMed ID: 11139761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
    Cardenal F; López-Cabrerizo MP; Antón A; Alberola V; Massuti B; Carrato A; Barneto I; Lomas M; García M; Lianes P; Montalar J; Vadell C; González-Larriba JL; Nguyen B; Artal A; Rosell R
    J Clin Oncol; 1999 Jan; 17(1):12-8. PubMed ID: 10458212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.